Abstract
Purpose. To evaluate carrier-mediated intestinal secretion of talinolol enantiomers in vivo and in vitro.
Methods. In clinical studies with i.v. and p.o. dosage of rac-talinolol (30 mg and 100 mg, resp.) performed in a small number of cholecystectomized patients total and partial clearances were determined on the basis of plasma, bile and urine concentrations. The dose-dependence of AUC was investigated in 12 healthy volunteers (25, 50, 100, and 400 mg rac-talinolol as single p.o. doses). Concentration-dependence of the permeability across Caco-2 cell monolayers included concentrations from 0.1 to 2.0 mM, inhibition by verapamil was tested at 0.5 mM.
Results. The total clearance as well as the apparent oral clearance (CL/F) were slightly higher for S-(–)-than for R-(+)-talinolol. Calculation of the partial clearances showed that also the residual clearance was higher for the S- than for the R-enantiomer. In the healthy volunteers, CL/F increased with increasing doses, while the S/R ratio decreased approaching unity for the highest dose. Also the results from Caco-2 cell permeation studies yielded a clear concentration-dependence with decreasing stereoselectivity for the higher concentration range. Permeability of both enantiomers was considerably higher for b→a than a→b transport, however, this difference disappeared when verapamil was added.
Conclusions. Although not very expressed, the detected stereoselectivities indicate a preferential absorption of R-(+)-talinolol in a lower concentration and dose range, which is most probably due to a moderate stereoselectivity at the carrier system involved in intestinal secretion.
Similar content being viewed by others
REFERENCES
Oberle R. L., Amidon G. L. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J. Pharmacokin. Biopharm. 15:529–544 (1987).
Langguth P., Lee K. M., Spahn-Langguth H., Amidon G. L. Variable gastric emptying and discontinuities in drug absorption profiles: Dependence of rates and extent of cimetidine absorption on motility phase and pH. Biopharm. Drug Dispos. 15:719–746 (1994).
Lipka E., Lee I-D., Langguth P., Spahn-Langguth H., Mutschler E., Amidon G. L. Celiprolol double peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs. J. Pharmacokin. Biopharm. submitted.
Spahn-Langguth H., Langguth P., Brockmeier D. The Pharmacokinetics of piretanide in humans: An update. In: Johnson S., Johnson F. N. (eds.) The Diuretic Agents 2: Piretanide. Marius Press, Carnforth, UK, 1993 pp. 11–29.
Lennernäs H., Regardh C. G. Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and doublepeaks in the plasma concentration-time profile. Pharm. Res. 10:879–883 (1993).
Langguth P., Khan P. J., Garrett E. R. Pharmacokinetics of morphine and its surrogates XI: Effect of simultaneously administered naltrexone and morphine on the pharmacokinetics and pharmacodynamics of each in the dog. Biopharm. Drug Dispos. 11:419–444 (1990).
Lennernäs H., Regardh C. G. Regional gastrointestinal absorption of the beta-blocker pafenolol in the rat and intestinal transit rate determined by movement of 14C-polyethylene glycol (PEG) 4000. Pharm. Res. 10:130–135 (1993).
Bartsch R., Femmer K., Heer S., Ploen U., Poppe H. Zur Pharmakologie der optisch aktiven Isomeren von Talinolol (Cordanum™). Dt. Gesundh.-Wesen; 34:1041–1046 (1979).
Wetterich U., Spahn-Langguth H., Terhaag B., Mutschler E. Bioanalytical method for talinolol enantiomers employing a chiral polyacrylamide stationary phase. Chirality submitted (1996).
Lennernäs H., Renberg L., Hoffmann K. J., Regardh C. G. Presystemic elimination of the beta-blocker pafenolol in the rat after oral and intraperitoneal administration and identification of a main metabolite in both rats and humans. Drug Metab. Dispos. 21:435–440 (1993).
Yamaguchi T., Ikeda C., Sekine Y. Intestinal absorption of a betaadrenergic blocking agent nadolol. I. Comparison of absorption behaviour of nadolol with those of other β-blocking agents in rats. Chem. Pharm. Bull. 34:3362–3369 (1986).
Yamaguchi T., Ikeda C., Sekine Y. Intestinal absorption of the beta-adrenergic blocking agent nadolol. II. Mechanism of the inhibitory effect on the intestinal absorption of nadolol by sodium cholate in rats. Chem. Pharm. Bull 34:3836–3843 (1986).
Lennernäs H., Regardh C. G. Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the betablocker pafenolol in the rat. Pharm. Res. 10:727–731 (1993).
Kuo S. M., Whitby B. R., Artursson P., Ziemniak J. A. The contribution of intestinal secretion to the dose-dependent absorption of celiprolol. Pharm. Res. 11:648–653 (1994).
Karlsson J., Kuo S. M., Ziemniak J., Artursson P. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol. 110:1009–1016 (1993).
Turnheim K., Lauterbach F. Interaction between intestinal absorption and secretion of monoquaternary ammonium compounds in guinea pigs—a concept for the absorption kinetics of organic cations. J. Pharmacol. Exp. Ther. 212:418–424 (1980).
Reymond J. P., Steimer J. L., Niederberger W. On the dose dependency of Cyclosporin A absorption and disposition in healthy volunteers. J. Pharmacokin. Biopharm. 16:331–335 (1988).
Arimori K., Nakano M. Dose-dependency in the exsorption of theophylline and the intestinal dialysis of theophylline by oral activated charcoal in rats. J. Pharm. Pharmacol. 40:101–105 (1988).
Kolars J. C., Schmiedlin-Ren P., Dobbins W. O., Schuetz J., Wrighton S. A., Watkins P. B. Heterogeneity of Cytochrome P450IIIA expression in rat gut epithelia. Gastroenterol. 102:1186–1198 (1992).
Augustijns P. F., Bradshaw T. P., Gan L.-S. L., Hendren R. W., Thakker D. R. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Commun. 197:360–365 (1993).
Hunter J., Jepson M. A., Tsuruos T., Simmons N. L., Hirst B. H. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. J. Biol. Chem. 268:14991–14997 (1993).
Endicott J. A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annual Reviews 58:137–171 (1989).
Thiebault F., Tsuruo T., Hamada H., Gottesman M. M., Pastan I., Willingham M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 1987;84:7735–7738.
Artursson P. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 79:476–482 (1990).
Hunter J., Hirst B. H., Simmons N. L. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res. 10:743–749 (1993).
Heinzel G., Woloszcak R., Thomann P. TOPFIT, Version 2.0, Gustav Fischer Verlag, Stuttgart (1993).
Oertel R. Analytik der Metabolite des Beta-Rezeptorenblockers Talinolol beim Menschen, Dissertation Universität Dresden (1994).
Terhaag B., Gramatte T., Richter K., Voss J., Feller K. The biliary elimination of the selective beta-receptor blocking drug talinolol in man. Int. J. Clin. Pharmacol. Ther. Toxicol. 27:170–172 (1989).
Raderer M., Scheithauer W. Clinical trials of agents that reverse multidrug resistance. Cancer 72:3553–3563 (1993).
Thews G., Mutschler E., Vaupel P., Anatomie, Physiologie, Pathophysiologie des Menschen. Wiss. Verlagsges., Stuttgart (1989).
Sachs L., Angewandte Statistik, Springer-Verlag, Berlin (1984).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wetterich, U., Spahn-Langguth, H., Mutschler, E. et al. Evidence for Intestinal Secretion as an Additional Clearance Pathway of Talinolol Enantiomers: Concentration- and Dose-dependent Absorption in Vitro and in Vivo. Pharm Res 13, 514–522 (1996). https://doi.org/10.1023/A:1016029601311
Issue Date:
DOI: https://doi.org/10.1023/A:1016029601311